Merck backs $150M vax developer in India

The Wellcome Trust in the U.K. and pharma giant Merck are joining forces to fund a $150 million non-profit vaccine developer to be based in India. The new joint venture will focus on developing inexpensive jabs for use in developing countries. And researchers will pursue a special focus on high-risk vaccine programs for neglected diseases. Article

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.